Novel carnosine synthase, and method for producing carnosine by using same

MYPI2025004164A0Undetermined Publication Date: 2024-07-13CJ CHEILJEDANG CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004164
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-13
Filing Date
2024-01-12
Publication Date
2024-07-13

AI Technical Summary

Technical Problem

Current methods for mass-producing carnosine industrially are cost-prohibitive due to the high requirement of substrate and ATP for enzymatic conversion.

Method used

A polypeptide with carnosine synthase activity, encoded by a specific polynucleotide, is used to produce carnosine through microbial fermentation, allowing for efficient production by modifying the amino acid sequence at specific positions to enhance enzyme activity.

Benefits of technology

This approach enables cost-effective and efficient production of carnosine, improving its industrial scalability and reducing production costs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are a polypeptide having carnosine synthase activity; a polynucleotide encoding the polypeptide; a microorganism including any one or more of the polypeptide, the polynucleotide, and a vector including the polynucleotide; a variant polypeptide having carnosine synthase activity; a polynucleotide encoding the variant polypeptide; a microorganism including any one or more of the variant polypeptide, the polynucleotide, and a vector including the polynucleotide; a composition for producing carnosine, the composition including any one or more of the polypeptide having carnosine synthase activity, the variant polypeptide, the microorganism, and a culture of the microorganism; a method for producing carnosine using any one or more of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism; and use of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism for producing carnosine.
Need to check novelty before this filing date? Find Prior Art

Description

Novel carnosine synthase and method for producing carnosine using the same

[0001] The present application relates to a polypeptide having carnosine synthase activity; a polynucleotide encoding the polypeptide; a microorganism comprising at least one of the polypeptide, the polynucleotide, and a vector comprising the polynucleotide; a variant polypeptide having carnosine synthase activity; a polynucleotide encoding the variant polypeptide; a microorganism comprising at least one of the variant polypeptide, the polynucleotide, and a vector comprising the polynucleotide; a composition for producing carnosine comprising at least one of the polypeptide having carnosine synthase activity, the variant polypeptide, the microorganism, and a culture thereof; a method for producing carnosine using at least one of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism; and uses of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism for producing carnosine.

[0002]

[0003] Carnosine is present in high concentrations in muscle and brain tissue, and is known to have antioxidant effects and muscle fatigue-improving effects as a physiologically active peptide.

[0004] Carnosine production can be achieved through enzymatic conversion (US 4359416 A), but because it requires a large amount of substrate and ATP, it is difficult to mass-produce it industrially due to cost issues.

[0005]

[0006] The problem to be solved in the present application is to provide a polypeptide having carnosine synthase activity; a polynucleotide encoding the polypeptide; a microorganism comprising at least one of the polypeptide, the polynucleotide, and a vector comprising the polynucleotide; a variant polypeptide having carnosine synthase activity; a polynucleotide encoding the variant polypeptide; a microorganism comprising at least one of the variant polypeptide, the polynucleotide, and a vector comprising the polynucleotide; a composition for producing carnosine comprising at least one of the polypeptide having carnosine synthase activity, the variant polypeptide, the microorganism, and a culture thereof; a method for producing carnosine using at least one of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism; and uses of the polypeptide having carnosine synthase activity, the variant polypeptide, and the microorganism for producing carnosine.

[0007]

[0008] One object of the present application is to provide a polypeptide having carnosine synthase activity, comprising the amino acid sequence of SEQ ID NO: 2.

[0009] Another object of the present application is to provide a polynucleotide encoding a polypeptide having the above-described carnosine synthase activity.

[0010] Another object of the present application is to provide a microorganism comprising at least one of a polypeptide having the above-described carnosine synthase activity, a polynucleotide encoding the same, and a vector comprising the above-described polynucleotide.

[0011] Another object of the present application is to provide a mutant polypeptide having carnosine synthase activity, wherein the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position are substituted with other amino acids.

[0012] Another object of the present application is to provide a polynucleotide encoding the mutant polypeptide.

[0013] Another object of the present application is to provide a microorganism comprising at least one of the mutant polypeptide, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

[0014] Another object of the present application is to provide a composition for producing carnosine, comprising at least one of a polypeptide having the carnosine synthase activity; a microorganism comprising at least one of a polypeptide having the carnosine synthase activity, a polynucleotide encoding the same, and a vector comprising the polynucleotide; a culture thereof; a microorganism comprising at least one of the variant polypeptide; the variant polypeptide, the polynucleotide encoding the same, and the vector comprising the polynucleotide; and a culture thereof.

[0015] Another object of the present application is to provide a method for producing carnosine, comprising a step of culturing the microorganism.

[0016] Another object of the present application is to provide a polypeptide having the carnosine synthase activity, a mutant polypeptide, and a use of the microorganism for producing carnosine.

[0017]

[0018] Efficient carnosine production is possible using the polypeptide, variant polypeptide, polynucleotide, microorganism, composition, and / or method having carnosine synthase activity of the present application.

[0019]

[0020] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.

[0021] Furthermore, those skilled in the art will recognize or be able to ascertain, through routine experimentation alone, numerous equivalents to the specific embodiments of this application described herein. Furthermore, such equivalents are intended to be encompassed by this application.

[0022] Additionally, numerous papers and patents are referenced and cited throughout this specification. The disclosures of these cited papers and patents are incorporated herein by reference in their entirety to provide a clearer understanding of the state of the art and the scope of the present invention.

[0023]

[0024] One aspect of the present application provides a polypeptide having carnosine synthase activity comprising the amino acid sequence of SEQ ID NO: 2.

[0025] In this application, the term "carnosine synthase" refers to an enzyme that can catalyze a reaction that produces carnosine using beta-alanine and L-histidine as substrates, and since it belongs to the ligase family, it can be used interchangeably with L-ligase and LAL. A specific example of carnosine synthase includes, but is not limited to, an enzyme comprising the amino acid sequence of SEQ ID NO: 2.

[0026] In the present application, the term “polypeptide having carnosine synthase activity” means a polypeptide having carnosine synthase activity comprising the amino acid sequence of SEQ ID NO: 2.

[0027] In one embodiment, the polypeptide having carnosine synthase activity in the present application may include, but is not limited to, the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 60% homology or identity thereto, as long as it has carnosine synthase activity. The amino acid sequence may be a polypeptide comprising SEQ ID NO: 2 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto, and may have, include, consist of, or essentially consist of an amino acid sequence having such homology or identity. It is not known whether the above sequence number 2 has the activity of carnosine synthase, but the amino acid sequence of sequence number 2 itself can be obtained from a known database such as NCBI's GenBank or KEGG (Kyoto Encyclopedia of Genes and Genomes). For example, the polypeptide having the above carnosine synthase activity may be derived from the genus Streptococcus or Streptococcus pneumoniae, but is not limited thereto.

[0028] In addition, although a protein including the amino acid sequence of SEQ ID NO: 2 is defined as an example of a carnosine synthase in the present application, it is obvious that a polypeptide having an amino acid sequence in which a part of the sequence is deleted, modified, substituted or added is also included within the scope of the present application, as long as it has the same homology or identity as above and exhibits the same or corresponding activity as the protein consisting of the amino acid sequence of SEQ ID NO: 2. For example, this does not exclude sequence additions that do not change the function of the protein before and after the amino acid sequence of SEQ ID NO: 2, mutations that may occur naturally, silent mutations or conservative substitutions thereof, and even in the case of such sequence additions or mutations, if it has the same or corresponding activity as the protein, it is obvious that it falls within the scope of the present application.

[0029] In addition, the carnosine synthase protein having the amino acid sequence of the above sequence number 2 may be encoded by a polynucleotide having or including a sequence of the sequence number 11 or a base sequence having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity with the sequence of the sequence number 11, or consisting of or consisting essentially of a sequence of the sequence number 11 or a base sequence having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity with the sequence of the sequence number 11, but is not limited thereto.

[0030]

[0031] Another aspect of the present application provides a variant polypeptide having carnosine synthase activity, wherein at least one of the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position is substituted with another amino acid.

[0032] In the present application, the term "variant polypeptide having carnosine synthase activity" refers to a variant polypeptide having carnosine synthase activity, wherein at least one of the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position is substituted with a different amino acid. In the present application, the "variant polypeptide having carnosine synthase activity" may be used interchangeably with "variant polypeptide".

[0033]

[0034] As an example of implementation, the reference carnosine synthase to be modified in the present application is the same as the polypeptide having the carnosine synthase activity described above.

[0035]

[0036] The term "variant" in this application refers to a polypeptide or protein in which one or more amino acids differ from the recited sequence by conservative substitution and / or modification, but the functions or properties of the polypeptide or protein are maintained.

[0037] The above variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide or protein and evaluating the properties of the modified polypeptide or protein. That is, the ability of the variant may be increased, unchanged, or decreased compared to the protein before the mutation. In addition, some variants may include variants in which one or more portions, such as the N-terminal leader sequence or the transmembrane domain, are deleted. Other variants may include variants in which portions are deleted from the N- and / or C-terminus of the mature protein. The term "variant" may be used interchangeably with terms such as variant, modification, variant polypeptide, mutated protein, mutation, and variant (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), and is not limited thereto as long as the term is used in the meaning of a mutation.

[0038] As used herein, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Typically, a conservative substitution may have little or no effect on the activity of the resulting protein or polypeptide. Furthermore, the variant may have one or more conservative substitutions while still retaining one or more biological activities.

[0039] These amino acid substitutions may generally occur based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartate; aromatic amino acids include phenylalanine, tryptophan, and tyrosine; and hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan. Additionally, amino acids can be classified into those with electrically charged side chains and those with uncharged side chains. Amino acids with electrically charged side chains include aspartic acid, glutamic acid, lysine, arginine, and histidine. Amino acids with uncharged side chains can be further classified into nonpolar amino acids or polar amino acids. Nonpolar amino acids include, but are not limited to, glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Polar amino acids include, but are not limited to, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.

[0040] Additionally, the polypeptide having the carnosine synthase activity and the variant polypeptide having the carnosine synthase activity may include deletions or additions of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of a protein that is involved in the transfer of the protein co-translationally or post-translationally. Furthermore, the polypeptide may be conjugated to other sequences or linkers so that the polypeptide can be identified, purified, or synthesized.

[0041]

[0042] As an example of implementation, the variant polypeptide of the present application may have carnosine synthase activity, wherein the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position are substituted with other amino acids.

[0043] In this application, "substitution with another amino acid" is not limited to an amino acid different from the amino acid prior to substitution. Furthermore, when this application expresses that "a specific amino acid has been substituted," it is self-evident that the amino acid has been substituted with an amino acid different from the amino acid prior to substitution, even if it is not specifically stated that it has been substituted with another amino acid.

[0044] The "N-position" of the present application may include the N-position and an amino acid position corresponding to the N-position. For example, it may include an amino acid position corresponding to any amino acid residue in a mature polypeptide disclosed in a specific amino acid sequence. For example, the specific amino acid sequence may be the amino acid sequence of SEQ ID NO: 2.

[0045] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a particular sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.

[0046] For example, any amino acid sequence can be aligned with SEQ ID NO: 2, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 2. For example, a sequence alignment algorithm such as that described in the present application can identify the position of an amino acid, or the position at which a modification such as a substitution, insertion, or deletion occurs, by comparing it to a query sequence (also referred to as a “reference sequence”).

[0047] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000), Trends Genet. 16: 276-277) can be used, but is not limited thereto, and any sequence alignment program known in the art, pairwise sequence comparison algorithm, etc. can be appropriately used.

[0048]

[0049] As an example of implementation, the variant polypeptide of the present application may have an amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and an amino acid corresponding to the 378th position substituted with other amino acids, and may have a sequence identity of 60% or more and less than 100%, specifically, a sequence identity of 80% or more and less than 100%, with the amino acid sequence of SEQ ID NO: 2, but is not limited thereto.

[0050] In one embodiment among the above-mentioned embodiments, the variant polypeptide of the present application may include an amino acid sequence having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or 99.9% homology or identity with the amino acid sequence of SEQ ID NO: 2, wherein the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position are substituted with other amino acids. In addition, it is obvious that a variant having an amino acid sequence in which a part of the sequence is deleted, modified, substituted, conservatively substituted or added is also included within the scope of the variant polypeptide of the present application, as long as it has the above-mentioned homology or identity and exhibits an activity corresponding to the variant polypeptide of the present application.

[0051]

[0052] As an example of implementation, the variant polypeptide of the present application may be one in which the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 is substituted with glutamic acid, and the amino acid corresponding to the 378th position is substituted with lysine.

[0053] As an example of implementation, the variant polypeptide of the present application may be one in which asparagine, an amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2, is substituted with glutamic acid, and histidine, an amino acid corresponding to the 378th position, is substituted with lysine.

[0054] In one embodiment among the above-described embodiments, the variant polypeptide of the present application may include an amino acid sequence in which the amino acid corresponding to position 108 in the amino acid sequence of SEQ ID NO: 2 is replaced with glutamic acid, the amino acid corresponding to position 378 is replaced with lysine and fixed, and has at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, 99.8% or 99.9% homology or identity with SEQ ID NO: 2.

[0055] In one embodiment, the variant polypeptide of the present application may comprise the amino acid sequence of SEQ ID NO: 8. The variant polypeptide of the present application may have, comprise, consist of, or consist essentially of an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 8.

[0056] In addition, it is obvious that a protein having an amino acid sequence in which a portion of the sequence other than the amino acids at positions 108 and 378 is deleted, modified, substituted, conservatively substituted or added can also be used in the present application, provided that the variant polypeptide of the present application has the same or corresponding activity as a protein consisting of the amino acid sequence of SEQ ID NO: 8. For example, if it has the same or corresponding activity as the variant polypeptide, it is not excluded that a sequence is added before or after the amino acid sequence that does not change the function of the protein, a mutation that may occur naturally, a silent mutation or a conservative substitution thereof, and it is obvious that even if such a sequence is added or mutation is present, it falls within the scope of the present application.

[0057] As an example of implementation, the mutant polypeptide of the present application may have enhanced activity of carnosine synthase compared to the polypeptide before mutation, but is not limited thereto.

[0058]

[0059] Another aspect of the present application provides a polynucleotide encoding a polypeptide having carnosine synthase activity of the present application.

[0060] Another aspect of the present application provides a polynucleotide encoding a variant polypeptide of the present application.

[0061] In this application, the term "polynucleotide" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, a DNA or RNA strand of a certain length or longer, and more specifically, a polynucleotide fragment encoding a polypeptide and / or a variant polypeptide having the carnosine synthase activity.

[0062] The polynucleotide encoding the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application may include, without limitation, any polynucleotide sequence encoding a polypeptide having an activity corresponding to the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application.

[0063] The polynucleotide encoding the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application may have various modifications made to the coding region within a range that does not change the amino acid sequence of the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application, taking into account the degeneracy of the codon or the codon preferred in the organism that is intended to express the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application. Therefore, taking into account codon degeneracy or preferred codons in an organism that is intended to express a polypeptide and / or a variant polypeptide having carnosine synthase activity of the present application, it is obvious that a polynucleotide sequence capable of encoding an amino acid sequence of a polypeptide and / or a variant polypeptide having carnosine synthase activity of the present application or a polypeptide having homology or identity therewith, a variant having a polynucleotide sequence in which some sequences are deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present application.

[0064] As an example of an embodiment, a polynucleotide encoding a polypeptide having carnosine synthase activity of the present application may have or include a base sequence having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7% or 99.9% homology or identity with the sequence of SEQ ID NO: 11, or may consist of or consist essentially of the nucleic acid sequence, but is not limited thereto.

[0065] For example, the polynucleotide encoding the polypeptide having carnosine synthase activity of the present application may be SEQ ID NO: 11 or a degenerated sequence thereof.

[0066] In one implementation example, a polynucleotide encoding a variant polypeptide of the present application may include, but is not limited to, a base sequence having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity with the sequence of SEQ ID NO: 11, wherein the codon encoding the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 and the amino acid corresponding to the 378th position are substituted with a codon encoding another amino acid (e.g., glutamic acid or lysine).

[0067] For example, a polynucleotide encoding a variant polypeptide of the present application may have a base sequence having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity with the sequence of SEQ ID NO: 11, wherein the codon encoding the amino acid corresponding to the 108th position from the N-terminus of SEQ ID NO: 2 may be a codon encoding glutamic acid and / or the codon encoding the amino acid corresponding to the 378th position may be a codon encoding lysine.

[0068] As another example, the polynucleotide encoding the variant polypeptide of the present application may be SEQ ID NO: 17 or a degenerated sequence thereof.

[0069] In one embodiment, a polynucleotide encoding a variant polypeptide of the present application may have, comprise, consist essentially of, or consist of, but is not limited to, a nucleic acid sequence having SEQ ID NO: 17, or having at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.7%, or 99.9% homology or identity thereto, and less than 100% identity thereto.

[0070]

[0071] In addition, the polynucleotide encoding the polypeptide having carnosine synthase activity of the present application and the polynucleotide encoding the variant polypeptide of the present application may include, without limitation, a probe that can be prepared from a known gene sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present application.

[0072] The above "stringent conditions" refer to conditions that allow specific hybridization between polynucleotides. These conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions in which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions in which washing is performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1ХSSC, 0.1% SDS, specifically 60°C, 0.1ХSSC, 0.1% SDS, and more specifically 68°C, 0.1ХSSC, 0.1% SDS, which are washing conditions of typical southern hybridization, are performed.

[0073] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Therefore, the polynucleotides of the present application may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.

[0074] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present application can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.

[0075] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).

[0076] As used herein, the terms "homology" or "identity" refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.

[0077] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.

[0078] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387(1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA / .](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database.

[0079] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a binary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and (2) a comparison matrix as disclosed by Gribskov et al. (1986) Nucl. Acids Res. 48:443, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979). 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for terminal gaps. Accordingly, the term "homology" or "identity" as used herein refers to the relevance between sequences.

[0080]

[0081] Another aspect of the present application provides a vector comprising a polynucleotide encoding a polypeptide having carnosine synthase activity and / or a variant polypeptide of the present application.

[0082] The above polynucleotide is as described in other aspects.

[0083] The above vector may be an expression vector for expressing the above polynucleotide in a microorganism, but is not limited thereto.

[0084] The term "vector" in this application may include a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. After being transformed into a suitable microorganism, the vector may replicate or function independently of the host genome, or may be integrated into the genome itself.

[0085] The vector used in the present application is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pDZ (Korean Patent No. 10-0924065 and International Patent Publication No. 2008-033001), pDZTn (Korean Patent No. 10-1126041), pDC, pDCM2, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. can be used.

[0086] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal integration. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.

[0087] The term "transformation" in this application refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a microorganism or into a microorganism, so that the polypeptide encoded by the polynucleotide can be expressed in the microorganism. The transformed polynucleotide can be located either within the chromosome of the microorganism or outside the chromosome, as long as it can be expressed in the microorganism. In addition, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide can be introduced in any form as long as it can be introduced into the microorganism and expressed. For example, the polynucleotide can be introduced into the microorganism in the form of an expression cassette, which is a genetic construct containing all the elements necessary for autonomous expression. The expression cassette can typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, all of which are operably linked to the polynucleotide. The expression cassette can be in the form of a self-replicating expression vector. Additionally, the polynucleotide may be introduced into a microorganism in its own form and operably linked to a sequence required for expression in the microorganism, but is not limited thereto.

[0088] The method for transforming the vector of the present application includes any method for introducing nucleic acids into cells, and can be performed by selecting an appropriate standard technique known in the art depending on the host cell. Examples thereof include, but are not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and lithium acetate-DMSO method.

[0089] Additionally, the term "operably linked" as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the polypeptide and / or variant polypeptide having carnosine synthase activity of the present application.

[0090]

[0091] Another aspect of the present application provides a microorganism comprising at least one of a polypeptide having carnosine synthase activity of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

[0092] Another aspect of the present application provides a microorganism comprising at least one of a variant polypeptide of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

[0093] The polypeptide, variant polypeptide, polynucleotide, and vector having the above carnosine synthase activity are as described in other aspects.

[0094] In this application, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone natural or artificial genetic modification. It may be a microorganism that has a specific mechanism weakened or strengthened due to reasons such as the insertion of an external gene or the enhancement or inactivation of an endogenous gene, and may be a microorganism that includes genetic modification for the production of carnosine. In this application, "strain" and "microorganism" may be used interchangeably without limitation with the same meaning.

[0095] The microorganism of the present application may be a microorganism in which the panD gene encoding the aspartate 1-decarboxylase protein, which is necessary for converting aspartic acid into beta-alanine, is introduced into the microorganism so that a microorganism that does not inherently have carnosine production ability has carnosine production ability, or a microorganism with carnosine production ability has carnosine production ability further enhanced, exhibits the activity of these proteins or has the activity enhanced. The aspartate 1-decarboxylase protein is not limited thereto as long as it exhibits the same or similar activity as the above-mentioned protein. As a specific example, the aspartic acid 1-decarboxylase protein may be composed of or include an amino acid sequence of SEQ ID NO: 9, but may be composed of or include an amino acid sequence that has at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology or identity with the amino acid sequence and exhibits activity corresponding to the aspartic acid 1-decarboxylase. In addition, it is obvious that a protein in which a part of the sequence is deleted, modified, substituted or added is also included in the aspartic acid 1-decarboxylase as long as it has the homology or identity and exhibits activity corresponding to the aspartic acid 1-decarboxylase. In addition, as a specific example, the polynucleotide encoding the aspartic acid 1-decarboxylase protein may be composed of or include the sequence of SEQ ID NO: 18. The polynucleotide may have various modifications made to the coding region within a range that does not change the amino acid sequence, taking into account the degeneracy of the codon or the codon preferred in the microorganism of the present application.Specifically, the polynucleotide may be composed of or include a base sequence having a homology or identity of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% with the base sequence of SEQ ID NO: 18, but is not limited thereto.

[0096]

[0097] As an example of an embodiment, the microorganism of the present application may be a microorganism belonging to the genus Enterbacter, Escherichia, Erwinia, Serratia, Providencia, Corynebacterium, or Brevibacterium. More specifically, it may be a microorganism belonging to the genus Corynebacterium, but is not limited thereto.

[0098] As an embodiment of the above-described embodiment, the microorganism of the present application is Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium stationis, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris, or Corynebacterium flavescens. Specifically, it may be Corynebacterium glutamicum, but is not limited thereto.

[0099]

[0100] As an example of an embodiment of the microorganism of the present application, a microorganism comprising at least one of a polypeptide having carnosine synthase activity of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide may have further enhanced activity of AroP (Aromatic amino acid transport protein) protein, but is not limited thereto.

[0101] As one embodiment of the above-described implementation example, the activity of the AroP protein may be further enhanced in a microorganism comprising at least one of a polypeptide having carnosine synthase activity of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide, thereby increasing the productivity of carnosine.

[0102] As an example of an embodiment of the microorganism of the present application, the microorganism may further have enhanced activity of the AroP protein, but is not limited thereto, and may comprise at least one of the variant polypeptide of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

[0103] In one embodiment of the above-described implementation example, the activity of the AroP protein may be further enhanced in a microorganism comprising at least one of the variant polypeptide of the present application; a polynucleotide encoding the same; and a vector comprising the polynucleotide, thereby increasing the productivity of carnosine.

[0104] In this application, the term "AroP protein" refers to an aromatic amino acid transport protein and may be used interchangeably with "AroP." The aromatic amino acids may include phenylalanine, tryptophan, and tyrosine. Furthermore, the AroP may be encoded by the aroP gene, but is not limited thereto.

[0105] In one embodiment, the AroP protein of the present application may include, but is not limited to, the amino acid sequence of SEQ ID NO: 19 or an amino acid sequence having at least 60% homology or identity thereto. The amino acid sequence may be a polypeptide comprising SEQ ID NO: 19 or an amino acid sequence having at least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity thereto. The sequence of SEQ ID NO: 19 can be obtained from a known database such as NCBI's GenBank or KEGG (Kyoto Encyclopedia of Genes and Genomes). In one example, the AroP protein to be strengthened may be derived from the genus Corynebacterium or Corynebacterium glutamicum, but is not limited thereto.

[0106] In addition, although a protein including the amino acid sequence of SEQ ID NO: 19 is defined as an example of the AroP protein in the present application, if it has the homology or identity as described above and has an activity identical or corresponding to that of the protein consisting of the amino acid sequence of SEQ ID NO: 19, it is obvious that a protein having an amino acid sequence in which a portion of the sequence is deleted, modified, substituted or added is also included within the scope of the AroP protein of the present application. For example, this does not exclude sequence additions that do not change the function of the protein before or after the amino acid sequence of SEQ ID NO: 19, mutations that may occur naturally, silent mutations or conservative substitutions thereof, and even in the case of such sequence additions or mutations, if it has an activity identical or corresponding to that of the protein, it is obvious that it falls within the scope of the present application.

[0107] In addition, the AroP protein having the amino acid sequence of SEQ ID NO: 19 may be encoded by a polynucleotide having or including a base sequence having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, and less than 100% homology or identity with the sequence of SEQ ID NO: 20, or consisting of or consisting essentially of the base sequence, but is not limited thereto.

[0108]

[0109] As used herein, the term "enhancement" of polypeptide or protein activity means that the activity of a polypeptide or protein is increased compared to its inherent activity. The term "enhancement" may be used interchangeably with terms such as activation, up-regulation, overexpression, and increase. The terms "activation," "enhancement," "up-regulation," "overexpression," and "increase" may encompass all manifestations of activity that was not originally present, or of activity that is enhanced compared to the inherent activity or activity prior to modification.

[0110] The above "intrinsic activity" refers to the activity of a specific polypeptide or protein that the parent strain or unmodified microorganism originally had before the change in traits due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with "activity before modification." The phrase "enhanced," "upregulated," "overexpressed," or "increased" the activity of a polypeptide or protein compared to the intrinsic activity means that the activity and / or concentration (expression amount) of the specific polypeptide or protein that the parent strain or unmodified microorganism originally had before the change in traits is improved.

[0111] The above enhancement can be achieved by introducing a foreign polypeptide or protein, or by enhancing the activity and / or concentration (expression level) of the foreign and / or endogenous polypeptide or protein. Whether the activity of the polypeptide or protein is enhanced can be determined by an increase in the level of activity of the polypeptide or protein, the expression level, or the amount of product excreted from the protein.

[0112] The enhancement of the activity of the above polypeptide or protein can be achieved by applying various methods well known in the art, and is not limited as long as the activity of the target polypeptide or protein can be enhanced compared to the microorganism before modification. Specifically, it may be achieved by using genetic engineering and / or protein engineering, which are routine methods of molecular biology and are well known to those skilled in the art, but is not limited thereto (e.g., Sitnicka et al. Functional Analysis of Genes. Advances in Cell Biology. 2010, Vol. 2. 1-16, Sambrook et al. Molecular Cloning 2012, etc.).

[0113] Specifically, the activity enhancement of the polypeptide or protein of the present application is

[0114] 1) Increase in the intracellular copy number of a polynucleotide encoding a polypeptide or protein;

[0115] 2) Replacing the gene expression control region on the chromosome that codes for a polypeptide or protein with a highly active sequence;

[0116] 3) Modification of the base sequence encoding the initiation codon or 5'-UTR region of a gene transcript encoding a polypeptide or protein;

[0117] 4) Modification of the amino acid sequence of the polypeptide or protein so as to enhance the activity of the polypeptide or protein;

[0118] 5) Modification of a polynucleotide sequence encoding a protein such that the polypeptide or protein activity is enhanced (e.g., modification of a polynucleotide sequence of a protein gene such that the protein activity is enhanced);

[0119] 6) Introduction of a foreign protein exhibiting the activity of a polypeptide or protein or a foreign polynucleotide encoding the same;

[0120] 7) Codon optimization of polynucleotides encoding polypeptides or proteins;

[0121] 8) Analyzing the tertiary structure of a polypeptide or protein to select and modify or chemically modify the exposed portion; or

[0122] 9) It may be a combination of two or more of the above 1) to 8), but is not particularly limited thereto.

[0123] The increase in the copy number of the gene as described above is not particularly limited thereto, but may be performed in a form operably linked to a vector, or by insertion into a chromosome within a host cell. Specifically, a vector capable of replicating and functioning independently of a host, to which a polynucleotide encoding the protein of the present application is operably linked, may be introduced into a host cell. Alternatively, a vector capable of inserting the polynucleotide into a chromosome within a host cell, to which the polynucleotide is operably linked, may be introduced into the chromosome of the host cell. The insertion of the polynucleotide into the chromosome may be accomplished by any method known in the art, for example, homologous recombination.

[0124] Next, modifying the expression control sequence to increase the expression of the polynucleotide may be performed by, but is not particularly limited to, inducing a sequence mutation in the nucleic acid sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof to further enhance the activity of the expression control sequence, or by replacing the nucleic acid sequence with a nucleic acid sequence having stronger activity. The expression control sequence may include, but is not particularly limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, a sequence regulating the termination of transcription and translation, etc.

[0125] A strong promoter may be linked upstream of the above polynucleotide expression unit instead of the original promoter, but is not limited thereto. Examples of known strong promoters include, but are not limited to, the CJ1 to CJ7 promoters (which may be used interchangeably with cj1 to cj7, respectively; U.S. Patent No. US 7662943 B2), the pyk promoter, the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (U.S. Patent No. US 10584338 B2), the O2 promoter (U.S. Patent No. US 10273491 B2), the tkt promoter, and the yccA promoter.

[0126] In addition, modification of a polynucleotide sequence on a chromosome may be performed, but is not particularly limited thereto, by inducing mutations in the expression regulatory sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof of the nucleic acid sequence to further enhance the activity of the polynucleotide sequence, or by replacing it with a polynucleotide sequence that has been improved to have stronger activity.

[0127]

[0128] In one implementation example, the variant polypeptide having carnosine synthase activity of the present application may have enhanced carnosine synthase activity by modifying its amino acid sequence such that the activity of an unmodified polypeptide having carnosine synthase activity (e.g., SEQ ID NO: 2) is enhanced. The polypeptide having carnosine synthase activity and the variant polypeptide in the present application may be further enhanced (e.g., by replacing the gene expression control region sequence thereof).

[0129] As another implementation example, the activity of the AroP protein of the present application may be enhanced by replacing the promoter, which is one of the gene expression control regions on the chromosome encoding the AroP protein, with a sequence having a strong activity (for example, replacing the wild-type promoter within the expression control region of aroP with the pyk or CJ7 promoter), but is not limited thereto.

[0130]

[0131] As an example of implementation, the microorganism of the present application may produce carnosine.

[0132] In this application, the term “carnosine” means a dipeptide composed of beta-alanine and L-histidine.

[0133] The term "carnosine-producing microorganism" in this application refers to a prokaryotic or eukaryotic microorganism capable of producing carnosine within the organism, and may include a microorganism in which carnosine-producing ability has been conferred on a parent strain that lacks carnosine-producing ability, or a microorganism that inherently possesses carnosine-producing ability. Carnosine-producing ability may be conferred or enhanced through species improvement.

[0134] For example, the microorganism of the present application may be a microorganism naturally having a variant polypeptide having carnosine synthase activity, a variant polypeptide having carnosine synthase activity, and / or a microorganism having the ability to produce carnosine; or a microorganism in which a variant polypeptide having carnosine synthase activity of the present application, a polynucleotide encoding the same (or a vector including the same), a variant of the present application or a polynucleotide encoding the same (or a vector including the same) is introduced into a parent strain that does not have the ability to produce carnosine, and / or is endowed with the ability to produce carnosine, but is not limited thereto. In addition, the microorganism of the present application may include all of a microorganism in which a gene on a chromosome encoding a polypeptide having carnosine synthase activity is mutated to include a polypeptide sequence having carnosine synthase activity of the present application, a microorganism including a variant polypeptide sequence having carnosine synthase activity of the present application, and a microorganism that introduces a vector including a polynucleotide encoding a polypeptide having carnosine synthase activity and / or a variant polypeptide of the present application to include a polypeptide having carnosine synthase activity and / or a variant polypeptide of the present application.

[0135] As another example, the microorganism of the present application may be, but is not limited to, a microorganism having a naturally enhanced AroP protein; a microorganism having a wild-type AroP; or a microorganism having enhanced AroP in a parent strain lacking the AroP protein. In addition, the microorganism of the present application may include a microorganism having an enhanced AroP by mutating the regulatory region of the aroP gene, and a microorganism having an enhanced AroP by introducing a vector containing the aroP gene.

[0136] The term "unmodified microorganism" in this application does not exclude strains that contain mutations that can occur naturally in microorganisms, and may refer to wild-type strains or natural strains themselves, or strains before their characteristics are changed by genetic mutations caused by natural or artificial factors. For example, the unmodified microorganism may refer to a strain into which the polypeptides and variant polypeptides having carnosine synthase activity described herein are not introduced or are introduced before they are introduced. The "unmodified microorganism" may be used interchangeably with "pre-modified strain," "pre-modified microorganism," "unmutated strain," "unmodified microorganism," or "reference microorganism."

[0137] For example, the microorganism with increased carnosine productivity may have an increase of about 1% or more, specifically, about 30% or more, compared to the carnosine productivity of the parent strain before mutation or the unmodified microorganism, but is not limited thereto, as long as it has a positive value of increase compared to the productivity of the parent strain before mutation or the unmodified microorganism. In another example, the recombinant strain with increased carnosine productivity may have an increase of about 1.01 times or more, specifically, about 1.30 times or more, compared to the parent strain before mutation or the unmodified microorganism, but is not limited thereto. The term “about” includes all of ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all values ​​in a range equal to or similar to the value following the term “about,” but is not limited thereto.

[0138] As another example, the non-modified microorganism, which is the target strain for comparing whether the carnosine production ability of the present application is increased, may be, but is not limited to, the ATCC13032 strain, which is a wild-type Corynebacterium glutamicum strain.

[0139] In one implementation example, a microorganism comprising a polypeptide having carnosine synthase activity of the present application, a polynucleotide encoding the same, or a vector comprising the polynucleotide may have increased carnosine production ability compared to a microorganism comprising any one of the polypeptides of SEQ ID NOs: 1 and 3 to 7, a polynucleotide encoding the same, or a combination thereof, but is not limited thereto. The polynucleotides of SEQ ID NOs: 10 and 12 to 16 of the present application may encode the polypeptides of SEQ ID NOs: 1 and 3 to 7, respectively, and the polypeptides of SEQ ID NOs: 1 and 3 to 7 may be encoded by the polynucleotides of SEQ ID NOs: 10 and 12 to 16, respectively, but are not limited thereto.

[0140] As an example of implementation, the variant polypeptide of the present application, the polynucleotide encoding it, or the microorganism comprising the polynucleotide may have increased carnosine production ability compared to a microorganism comprising any one of the polypeptides of SEQ ID NOs: 1 to 7, the polynucleotide encoding it, or a combination thereof, but is not limited thereto.

[0141] As an example of implementation, a microorganism in which the activity of the AroP protein is further enhanced in the present application may have increased carnosine production ability compared to a microorganism in which the activity of the AroP protein is not enhanced.

[0142]

[0143] Another aspect of the present application provides a composition for producing carnosine, comprising at least one of a polypeptide having carnosine activity of the present application; a microorganism comprising at least one of a polypeptide having carnosine activity of the present application, a polynucleotide encoding the same, and a vector comprising the polynucleotide; a culture thereof; a variant polypeptide; a microorganism comprising at least one of the variant polypeptide, the polynucleotide encoding the same, and the vector comprising the polynucleotide; and a culture of the microorganism.

[0144] The polypeptide, variant polypeptide, polynucleotide, vector, microorganism, and carnosine having the above carnosine activity are as described in other aspects.

[0145] The composition of the present application may further comprise any suitable excipient commonly used in compositions for producing carnosine, including but not limited to preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.

[0146]

[0147] In one specific example, each component present in the composition of the present application may be included in a microbiologically effective amount, or an amount that can be suitably present in the composition for production.

[0148] In the present application, the culture may include any culture, such as a dried product, diluted product, concentrate, culture filtrate, or fermented product.

[0149]

[0150] Another aspect of the present application provides a method for producing carnosine, comprising the step of culturing the microorganism of the present application in a medium.

[0151] The above microorganisms and carnosine are as described in other aspects.

[0152] In this application, the term "cultivation" refers to growing the microorganism of this application under appropriately controlled environmental conditions. The culturing process of this application can be performed using any suitable medium and culture conditions known in the art. This culturing process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the culturing process may be batch, continuous, and / or fed-batch, but is not limited thereto.

[0153] In this application, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of this application, and supplies nutrients and growth factors, including water, which is essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the microorganism of this application may be any medium used for culturing general microorganisms without particular limitation. However, the microorganism of this application may be cultured under aerobic conditions in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin, while controlling temperature, pH, etc. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].

[0154] In the present application, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc., organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc.; glycerol, propanediol, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.

[0155] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.

[0156] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.

[0157] In addition, during the cultivation of the microorganism of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. In addition, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain the anaerobic and microaerobic state, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.

[0158] In the culture of the present application, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.

[0159] Carnosine produced by the culture of the present invention may be secreted into the medium or remain within the cells.

[0160]

[0161] In one specific example, the method for producing carnosine of the present application may further include, for example, prior to the culturing step, a step of preparing a microorganism of the present application, a step of preparing a medium for culturing the strain, or a combination thereof (in any order).

[0162] In one specific example, the method for producing carnosine of the present application may further comprise a step of recovering carnosine from the culture medium (the medium in which the culture is performed) or the microorganism of the present application. The recovering step may be additionally included after the culturing step.

[0163] The above recovery may be performed by collecting L-carnosine using a suitable method known in the art according to the culture method of the microorganism of the present application, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallizing protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and carnosine may be recovered from a medium or microorganism using a suitable method known in the art.

[0164] Additionally, the carnosine production method of the present application may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, if the carnosine production method of the present application includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.

[0165]

[0166] Another aspect of the present application provides a polypeptide having carnosine synthase activity of the present application; a variant polypeptide; and a use of the microorganism of the present application for producing carnosine.

[0167] The polypeptide, mutant polypeptide, microorganism, and carnosine having the above carnosine synthase activity are as described in other aspects.

[0168]

[0169] The present application will be described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present application and are therefore not intended to limit the scope of the present application. Furthermore, technical details not described herein can be readily understood and implemented by those skilled in the technical field of the present application or similar fields.

[0170]

[0171] Example 1. Search and screening of novel carnosine synthase.

[0172] Using the amino acid sequence of Bacillus carnosine synthase as the query sequence, PSI-BLAST was performed against the NCBI and Kegg databases. As a result, 20 candidate genes considered to be enzymes capable of synthesizing carnosine and organisms harboring these genes were selected. Considering similarity to the query sequence, seven microorganisms and their derived enzymes were selected, as shown in Table 1 below.

[0173]

[0174] Sequence Microbial Protein Registration Number 1 Bacillus subtilis 168CAB15798.12 Streptococcus pneumoniae CVN04298.13 Alkalihalobacillus halodurans MBV7318856.14 Priestia megaterium WP_116516826.15 Pseudomonas syringae BAJ15424.16 Pseudomonas syringae pv. phaseolicola AAZ37741.17 Bacillus pumilus GM828960.1

[0175]

[0176] Example 2. Production of expression vectors introducing various carnosine synthetase enzymes.

[0177] Carnosine synthetase derived from the seven species selected in Example 1 above (Bacillus subtilis, Streptococcus pneumoniae, Alkalihalobacillus halodurans, Pristia megaterium, Pseudomonas syringae, Pseudomonas syringae pv. phaseolicola, and Bacillus pumilus) each have an amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 7. Information on genes encoding the enzymes and surrounding base sequences was obtained from the National Institutes of Health (NIH GenBank) (accession numbers CAB15798.1, CVN04298.1, MBV7318856.1, WP_116516826.1, BAJ15424.1, AAZ37741.1, and GM828960.1, respectively, in that order).

[0178] Afterwards, gene fragments for vector production were obtained by performing PCR using the obtained gene sequences as templates.

[0179] At this time, the polymerase is Solg TM Pfu-X DNA polymerase was used, and PCR amplification conditions were as follows: denaturation at 95°C for 3 minutes, followed by 30 cycles of denaturation at 95°C for 20 seconds; annealing at 56°C for 40 seconds; and polymerization at 72°C for 2 minutes, followed by polymerization at 72°C for 5 minutes.

[0180] In order to amplify a gene derived from Bacillus subtilis, primers having sequence numbers 21 and 22 as shown in Table 2 below were prepared, and PCR was performed using the polymerase and PCR amplification conditions as described above, resulting in a 1,419 bp gene fragment.

[0181] In order to amplify a gene derived from Streptococcus pneumoniae, primers having sequence numbers 23 and 24 as shown in Table 2 below were prepared, and PCR was performed in the same manner, resulting in a 1,422 bp gene fragment.

[0182] In order to amplify a gene derived from Alkaline Halobacillus halodurans, primers having sequence numbers 25 and 26 as shown in Table 2 below were prepared, and PCR was performed to obtain a 1,419 bp gene fragment.

[0183] In order to amplify a gene derived from Pristia megaterium, primers of sequence numbers 27 and 28 as shown in Table 2 below were prepared, and PCR was performed in the same manner, resulting in a 1,422 bp gene fragment.

[0184] In order to amplify a gene derived from Pseudomonas syringae, primers having sequence numbers 29 and 30 as shown in Table 2 below were prepared, and PCR was performed in the same manner, resulting in a 1,260 bp gene fragment.

[0185] In order to amplify a gene derived from Pseudomonas syringae pv. phaseolicola, primers of sequence numbers 31 and 32 as shown in Table 2 below were prepared, and PCR was performed in the same manner, resulting in a 1,245 bp gene fragment.

[0186] In order to amplify a gene derived from Bacillus pumilus, primers of sequence numbers 33 and 34 as shown in Table 2 below were prepared, and PCR was performed in the same manner to obtain a 1,434 bp gene fragment.

[0187]

[0188] SEQ ID NO: NAME Sequence 21BsLAL_FGAGGAGATCAAAACAATGGAGCGTAAAACGGTGCTG22BsLAL_RCGGTGGCGGCCGCTCTAGATCACACCGGGAGGACATATTTC23SpLAL_FGAGGAGATCAAAACAATGAGCAAGAAGACTGTTCTTG24SpLAL_RCGCGGTGGCGGCCGCTCTAGATTAGCCCTTCACAAGCT CGT25AhLAL_FGAGGAGATCAAAACAATGGAACGTAAGACTGTACTGG26AhLAL_RGCGGTGGCGGCCGCTCTAGATTAGACCGGCAGAACGTACT27PmLAL_FGAGGAGATCAAAACAATGAAGCGTAAGACTGTTCTGG28PmLAL_RCGCGGTGGCGGCCGCTCTAGATTACGTAGTCACAGGCACGC29P sLAL_FGAGGAGATCAAAACAATGACGCAGGCAAAAGAGAATA30PsLAL_RCGCGGTGGCGGCCGCTCTAGATTACTGGACGGAAAAGAGCC31PspLAL_FGAGATCAAACAATGAAAAAGATTATTCTCATTGAAACC32PspLAL_RCGGTGGCGGCCGCTCTAGATTAAAGAGGTTCTGACGAATCG33Bp LAL_FGAGGAGATCAAAACAATGGTCCTTAGCCTGTCGAAAAAG34BpLAL_RCGGTGGCGGCCGCTCTAGATCAACCTTTCACCAACTCATCCATAAG35Po2_FCCTGCAGCCCGGGGGATCCCAATAATCGTGAATTTTGGCAGC36Po2_RGGCGGCCGCTCTAGATGTTTTGATCTCCTCCAATAATCTATG

[0189]

[0190] In addition, to secure the promoter, PCR was performed using the o2 promoter (US 10273491 B2) as a template and primers of sequence numbers 35 and 36 as shown in Table 2 above.

[0191] Each gene expression vector was obtained by linking the amplified o2 promoter region, gene fragments derived from seven microorganisms, and the vector pCES208 ("Construction of heat-inducible expression vector of Corynebacterium glutamicum and C. ammoniagenes: fusion of lambda operator with promoters isolated from C. ammoniagenes." Journal of microbiology and biotechnology 18.4 (2008): 639-647.) digested with XbaI restriction enzyme using an In-fusion Cloning Kit.

[0192] Accordingly, the vector containing a gene derived from Bacillus subtilis was named "pCES208-Po2-BsLAL", the vector containing a gene derived from Streptococcus pneumoniae was named "pCES208-Po2-SpLAL", the vector containing a gene derived from Alkalihalobacillus halodurans was named "pCES208-Po2-AhLAL", the vector containing a gene derived from Pristia megaterium was named "pCES208-Po2-PmLAL", the vector containing a gene derived from Pseudomonas syringae was named "pCES208-Po2-PsLAL", the vector containing a gene derived from Pseudomonas syringae pv. phaseolicola was named "pCES208-Po2-PspLAL", and the vector containing a gene derived from Bacillus pumilus was named "pCES208-Po2-BpLAL".

[0193]

[0194] Example 3. Production of a Corynebacterium strain producing beta-alanine and L-histidine.

[0195] To evaluate the carnosine synthesis activity of the above enzymes, we attempted to construct a Corynebacterium strain that produces beta-alanine and L-histidine. Accordingly, a vector was constructed to insert panD, a gene required for converting aspartic acid produced in a Corynebacterium glutamicum strain into beta-alanine, into the genomic DNA of the strain.

[0196] To amplify the panD gene, primers having sequence numbers 37 and 38 as shown in Table 3 below were prepared using the chromosomal DNA of Corynebacterium glutamicum wild type ATCC13032 as a template, and PCR was performed in the same manner as in Example 2, resulting in a 411 bp gene fragment.

[0197] To obtain the o2 promoter derived from Corynebacterium glutamicum, PCR was performed using the Corynebacterium glutamicum genomic DNA as a template and primers of sequence numbers 39 and 40 as shown in Table 3 below.

[0198]

[0199] SEQ ID NO NAME Sequence 37panD_FGGAGGAGATCAAAACAATGCTGCGCACCATCCTCG38panD_RCGTAGCCTTGGAATCCACTAAATGCTTCTCGACGTCAAAAG39Po2panD_FGGCTCCCGCGGTGAACAATAATCG TGAATTTTGGCAGC40Po2panD_RGGATGGTGCGCAGCATTGTTTTGATCTCCTCCAATAATC41check_Po2-panD_FCCTGGGCTAGCGGTGTAG42check_Po2-panD_RCTGCTCTTTAAATCCGCGG

[0200]

[0201] The amplified o2 promoter region, the panD gene fragment, and the chromosomal transformation vector pDZTn (Korean Patent No. 10-1126041) digested with SpeI restriction enzyme were cloned using the Gibson assembly method (DG Gibson et al., NATURE METHODS, VOL.6 NO.5, MAY 2009, NEBuilder HiFi DNA Assembly Master Mix) to obtain a recombinant plasmid, and the obtained plasmid was named pDZTn-Po2-panD. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar number and then storing it at 50℃ for 1 hour.

[0202] The constructed pDZTn-Po2-panD vector was transformed into the wild-type Corynebacterium glutamicum ATCC13032 strain by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), and a second crossover process was performed to obtain a strain in which one copy of the Po2-panD gene was inserted between transposon genes on the chromosome. The genetic manipulation was confirmed through PCR using primers of sequence numbers 41 and 42 as shown in Table 3, which can amplify external regions of the upstream and downstream regions of the homologous recombination site where the gene was inserted, and genome sequencing.

[0203] The strain thus obtained was named Corynebacterium glutamicum "ATCC13032::Po2-panD".

[0204]

[0205] Example 4. Production of Corynebacterium strains with various carnosine synthetase enzymes.

[0206] The vectors produced in Example 2 were transformed into the Corynebacterium glutamicum ATCC13032::Po2-panD strain produced in Example 3 by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), thereby obtaining seven strains in which each gene was introduced.

[0207] At this time, the strain into which pCES208-Po2-BsLAL was introduced was called "ATCC13032::Po2-panD-BsLAL", the strain into which pCES208-Po2-SpLAL was introduced was called "ATCC13032:: Po2-panD-SpLAL", the strain into which pCES208-Po2-AhLAL was introduced was called "ATCC13032:: Po2-panD-AhLAL", the strain into which pCES208-Po2-PmLAL was introduced was called "ATCC13032:: Po2-panD-PmLAL", the strain into which pCES208-Po2-PsLAL was introduced was called "ATCC13032:: Po2-panD-PsLAL", and the strain into which pCES208-Po2-PspLAL was introduced was called "ATCC13032:: The strain into which pCES208-Po2-BpLAL was introduced was named "ATCC13032:: Po2-panD-PspLAL", and the strain into which pCES208-Po2-BpLAL was introduced was named "ATCC13032:: Po2-panD-BpLAL", respectively.

[0208]

[0209] Example 5. Confirmation of carnosine production by Corynebacterium strains with various carnosine synthetase enzymes introduced.

[0210] To confirm the carnosine production of the seven Corytebacterium glutamicum strains produced in Example 4, fermentation titer experiments were conducted. Colonies of each strain were subcultured in nutrient medium and then cultured in fermentation medium for 48 hours. The medium composition used was as follows.

[0211]

[0212] Nutrient medium

[0213] Glucose 1%, meat juice 0.5%, polypeptone 1%, sodium chloride 0.25%, yeast extract 0.5%, agar 2%, urea 0.2%, pH 7.2

[0214] Fermentation medium

[0215] Glucose 6%, calcium carbonate 3%, ammonium sulfate 2%, sugarcane molasses 1%, yeast extract 0.1%, potassium monophosphate 0.4%, magnesium sulfate 0.3%, isoleucine 0.026%, nicotinamide 36 mg / L, iron sulfate 2.5 mg / L, manganese sulfate 1.175 mg / L, biotin 0.05 mg / L

[0216]

[0217] After cultivation under the above conditions was completed, the carnosine concentration in each medium was measured using HPLC. The carnosine concentrations produced by the seven strains are shown in Table 4 below.

[0218]

[0219] Strain nameCarnosine (g / L)ATCC13032::Po2-panD-BsLAL0.9ATCC13032::Po2-panD-SpLAL1.5ATCC13032::Po2-panD-AhLAL0.9ATCC13032: :Po2-panD-PmLAL0.3ATCC13032::Po2-panD-PsLAL0ATCC13032::Po2-panD-PspLAL0ATCC13032::Po2-panD-BpLAL1.1

[0220]

[0221] As shown in Table 4 above, among the various carnosine synthetase enzymes, ATCC13032::Po2-panD-SpLAL, into which an enzyme derived from Streptococcus pneumoniae was introduced, produced 1.5 g / L of carnosine. This was confirmed to be approximately 0.6 g / L (approximately 67%) higher than the carnosine concentration produced by ATCC13032::Po2-panD-BsLAL, into which an enzyme derived from Bacillus subtilis was introduced, which was previously reported, and 0.4 g / L (approximately 36%) higher than the carnosine concentration produced by ATCC13032::Po2-panD-BpLAL, into which an enzyme derived from Bacillus pumilus was introduced.

[0222] From the above results, it was confirmed that the enzyme derived from Streptococcus pneumoniae had the highest carnosine synthesis activity, and that there were cases where carnosine was not produced depending on the origin of the carnosine synthase.

[0223]

[0224] Example 6. Carnosine production by a strain of Corynebacterium spp. into which a mutant Streptococcus pneumoniae-derived enzyme has been introduced.

[0225] Example 6-1. Production of a strain containing a mutant Streptococcus pneumoniae-derived enzyme.

[0226] Two amino acid mutations were introduced into the Streptococcus pneumoniae-derived enzyme with the highest carnosine synthesis activity, selected through Example 5 above. Specifically, asparagine, the 108th amino acid in the enzyme sequence, was substituted with glutamic acid, and histidine, the 378th amino acid, was substituted with lysine, verifying an improvement in carnosine synthesis activity.

[0227] To this end, first, in order to substitute asparagine, the 108th amino acid of sequence number 2, with glutamic acid, a set of primers (mutagenic primers) of sequence numbers 43 and 44 as shown in Table 5 was produced using pCES208-Po2-SpLAL produced in Example 2 as a template.

[0228]

[0229] Mutant SpLAL plasmid sequence number # Base sequence pCES208-Po2-SpLAL N108E43CGATTACGACGAACGAAGAACTGTTTATTGCCCCAA44TTGGGGCAATAAACAGTTCTTCGTTCGTCGTAATCGpCES208-Po2-SpLALN108E / H378K45CCACACGTTTTATGTGGCAGATTGTAAACTTTATCCTCAACATTTTAAAGAAT46ATTCTTTAAAATGTTGAGGATAAAGTTTACAATCTGCCACATAAAACGTGTGG

[0230] Using the above primer set, a PCR mixture as shown in Table 6 below was prepared, and site-direction mutagenesis PCR was performed as shown in Table 7 below.

[0231]

[0232] Site-Direction Mutagenesis PCR composition unit (ul)10X pfu-

[0233] Cycle Temperature Time 195 ℃ 1 min 1895 ℃ 50 sec 60 ℃ 50 sec 68 ℃ 9 min 168 ℃ 7 min

[0234]

[0235] 1 μl of DpnI restriction enzyme was added to the PCR-completed mixture and left at 37°C for 1 hour. 3 μl of DpnI-treated DNA was transformed into DH5a competent cells to obtain the pCES208-Po2-SpLAL N108E plasmid.

[0236] Additionally, in order to replace the 378th amino acid, histidine, with lysine, the pCES208-Po2-SpLAL N108E / H378 plasmid was obtained in the same manner as above using the above-constructed pCES208-Po2-SpLAL N108E plasmid as a template and the respective mutagenic primer sets indicated in SEQ ID NOs: 45 and 46 in Table 5. Sequencing confirmed that each mutation indicated in the plasmid in Table 5 had been replaced, and as a result, the sequence of SEQ ID NO: 8 was obtained.

[0237] The above-constructed pCES208-Po2_SpLAL N108E / H378K vector was transformed into the Corynebacterium glutamicum ATCC13032::Po2-panD strain constructed in Example 3 by electroporation, and a strain in which a mutant SpLAL gene (N108E / H378K) was inserted was obtained. The strain was named "ATCC13032::Po2-panD-SpLAL N108E / H378K".

[0238]

[0239] Example 6-2: Confirmation of carnosine production by a Corynebacterium strain containing a mutant Streptococcus pneumoniae-derived enzyme.

[0240] In order to confirm the carnosine production amount of the Corynebacterium glutamicum ATCC13032::Po2-panD-SpLAL N108E / H378K strain produced in Example 6-1, the production amount of carnosine was measured using HPLC after culturing in the same manner as in Example 5.

[0241]

[0242] Strain name Carnosine production (g / L) ATCC13032::Po2-panD-SpLAL1.5 ATCC13032::Po2-panD-SpLAL N108E / H378K2.1

[0243]

[0244] As shown in Table 8 above, the concentration of carnosine produced by a microorganism introduced with a mutant SpLAL enzyme (N108E / H378K) was confirmed to be approximately 0.6 g / L (approximately 40%) higher than the concentration of carnosine produced by a microorganism introduced with a wild-type SpLAL enzyme.

[0245] From the above results, it was confirmed that the N108E / H378K mutation increases the carnosine production ability of a microorganism having the enzyme.

[0246]

[0247] Example 7. Enhanced carnosine productivity of Corynebacterium strains with enhanced AroP.

[0248] Example 7-1. Production of strains with enhanced AroP

[0249] To enhance AroP in Corynebacterium strains, a vector was constructed to introduce the pyk promoter and cj7 promoter (US 7662943 B2).

[0250] In order to amplify the pyk promoter, primers of SEQ ID NOs: 47 and 48 as shown in Table 9 below were prepared using the chromosomal DNA of Corynebacterium glutamicum wild type ATCC13032 as a template, and PCR was performed in the same manner as in Example 2, resulting in a 500 bp gene fragment. In order to obtain gene fragments required for insertion into the host genomic DNA, SEQ ID NOs: 49 and 50 and SEQ ID NOs: 51 and 52 as shown in Table 9 below were prepared, and PCR was performed in the same manner as in Example 2, resulting in a 501 bp and 500 bp gene fragment.

[0251]

[0252] SEQ ID NO: Name Sequence 47pyk_FGGTTTACGGTTGATACGTATTTGCACTCTACGTAGCTGG48pyk_RCTTCATTAGATTTAGCCATGCCCATAAGCCTAGTACGTC49Aarm_FgagctcggtacccggggatccGTTCCCCCTGGAGTCCG50A arm_pyk_RCTACGTAGAGTGCAAATACGTATCAACCGTAAACCCACATG51Barm_pyk_FGTACTAGGCTTATGGGCATGGCTAAATCTAATGAAGGGC52Barm_RcctgcaggtcgactctagaCCAATGATGAGGAAAGCGATG

[0253]

[0254] The amplified pyk promoter region and the two gene fragments obtained above were ligated into the pDZ vector (Korean Patent No. 10-0924065 and International Patent Publication No. 2008-033001) cut with restriction enzymes BamHI and XbaI using an In-fusion Cloning Kit to produce a gene introduction vector, which was named "pDZ-pyk (AroP)."

[0255] In addition, in order to amplify the CJ7 promoter, primers of SEQ ID NOs: 53 and 54 as shown in Table 10 below were prepared using the chromosomal DNA of Corynebacterium glutamicum wild type ATCC13032 as a template, and PCR was performed in the same manner as in Example 2, resulting in a 317 bp gene fragment. In order to obtain gene fragments necessary for insertion into the host genomic DNA, SEQ ID NOs: 49 and 55 and SEQ ID NOs: 56 and 52 as shown in Table 9 above and Table 10 below were prepared, and PCR was performed in the same manner as in Example 2, resulting in a 501 bp and 500 bp gene fragment.

[0256]

[0257] SEQ ID NO: Name Sequence 53cj7_FGGGTTTACGGTTGATACAGAAACATCCCAGCGCTACTAATAG54cj7_RCTTCATTAGATTTAGCCATAGTGTTTCCTTTCGTTGGGTAC55Aarm_cj7_RGTAGCGCTGGGATGTTTCTGTATCAACCGTAAACCCACATG56Barm_cj7_FCCCAACGAAAGGAAACACTATGGCTAAATCTAATGAAGGGC

[0258]

[0259] The amplified CJ7 promoter region and the two gene fragments obtained above were ligated into the pDZ vector (Korean Patent No. 10-0924065 and International Patent Publication No. 2008-033001) digested with restriction enzymes BamHI and XbaI using an In-fusion Cloning Kit to produce a gene introduction vector, which was named "pDZ-cj7(AroP)".

[0260] The ATCC13032::Po2-panD-SpLAL N108E / H378K strain constructed in Example 6-1 was transformed with the constructed pDZ-pyk(AroP) vector and pDZ-cj7(AroP) vector, respectively, by electroporation (Appl. Microbiol. Biotechnol. (1999) 52:541-545), and then a strain in which a promoter was inserted in front of the AroP gene on the chromosome was obtained through a second crossing over process. The genetic manipulation was confirmed through PCR using primers of sequence numbers 57 (check_AroP_F; CTCTGCGGTCCCGCGGAC) and 58 (check_AroP_R; CGTGATCACCGATGAAGTTTG), which can amplify the external regions of the upstream and downstream regions of the homologous recombination site where the gene was inserted, and genome sequencing.

[0261] The Corynebacterium glutamicum strains thus obtained were named "ATCC13032::Po2-panD-SpLAL (N108E / H378K)-PpykAroP" and "ATCC13032::Po2-panD-SpLAL (N108E / H378K)-Pcj7AroP", respectively.

[0262]

[0263] Example 7-2. Confirmation of carnosine production by strains with enhanced AroP

[0264] To confirm the carnosine production of ATCC13032::Po2-panD-SpLAL (N108E / H378K)-PpykAroP strain and ATCC13032::Po2-panD-SpLAL (N108E / H378K)-Pcj7AroP strain, each strain was cultured using the same method as in Example 5, and the carnosine production was measured using HPLC.

[0265]

[0266] Strain name Carnosine production (g / L) ATCC13032::Po2-panD-SpLAL N108E / H378K2.1 ATCC13032::Po2-panD-SpLAL (N108E / H378K)-PpykAroP2.5 ATCC13032::Po2-panD-SpLAL(N108E / H378K)-Pcj7AroP2.7

[0267]

[0268] As shown in Table 11, the concentration of carnosine produced by ATCC13032::Po2-panD-SpLAL (N108E / H378K)-PpykAroP, into which the pyk promoter was introduced, was confirmed to be about 0.4 g / L (about 19%) higher than the concentration of carnosine produced by ATCC13032::Po2-panD-SpLAL N108E / H378K, and the concentration of carnosine produced by ATCC13032::Po2-panD-SpLAL (N108E / H378K)-Pcj7AroP, into which the cj7 promoter was introduced, was confirmed to be about 0.6 g / L (about 29%) higher than the concentration of carnosine produced by ATCC13032::Po2-panD-SpLAL N108E / H378K.

[0269] From the above results, it was confirmed that AroP enhancement increases the carnosine production ability of microorganisms.

[0270]

[0271] From the above description, those skilled in the art will understand that the present application can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of this application should be interpreted to include all changes or modifications derived from the meaning and scope of the following claims and their equivalents, rather than the detailed description above.

Claims

1. A polypeptide having carnosine synthase activity, comprising the amino acid sequence of sequence number 2.

2. A polynucleotide encoding a polypeptide having the carnosine synthase activity of paragraph 1.

3. A microorganism comprising at least one of a polypeptide having carnosine synthase activity of the first paragraph, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

4. In the third paragraph, the microorganism is a microorganism that produces carnosine.

5. In the third paragraph, the microorganism is a microorganism in which the activity of AroP (Aromatic amino acid transport protein) protein is further enhanced.

6. A microorganism according to claim 5, wherein the AroP protein comprises an amino acid sequence of SEQ ID NO:

19.

7. In the third paragraph, the microorganism is a microorganism of the genus Corynebacterium.

8. A microorganism according to claim 3, wherein the microorganism is Corynebacterium glutamicum.

9. A mutant polypeptide having carnosine synthase activity, wherein the amino acid corresponding to the 108th position from the N-terminus of sequence number 2 and the amino acid corresponding to the 378th position are substituted with other amino acids.

10. In the 9th paragraph, the mutant polypeptide is a mutant polypeptide in which the amino acid corresponding to the 108th position from the N-terminus of sequence number 2 is substituted with glutamic acid, and the amino acid corresponding to the 378th position is substituted with lysine.

11. In claim 9, the mutant polypeptide is a mutant polypeptide in which asparagine, an amino acid corresponding to the 108th position from the N-terminus of sequence number 2, is substituted with glutamic acid, and histidine, an amino acid corresponding to the 378th position, is substituted with lysine.

12. A variant polypeptide according to claim 9, wherein the variant polypeptide comprises the amino acid sequence of SEQ ID NO:

8.

13. A polynucleotide encoding a mutant polypeptide of claim 9.

14. A microorganism comprising at least one of the variant polypeptide of paragraph 9, a polynucleotide encoding the same, and a vector comprising the polynucleotide.

15. A microorganism according to claim 14, wherein the microorganism produces carnosine.

16. In claim 14, the microorganism is a microorganism in which the activity of the AroP protein is further enhanced.

17. A composition for producing carnosine, comprising at least one of the following: a polypeptide having carnosine activity of claim 1; a microorganism comprising at least one of the polypeptide having carnosine activity of claim 1, a polynucleotide encoding the same, and a vector comprising the polynucleotide; a culture thereof; a mutant polypeptide of any one of claims 9 to 12; a microorganism comprising at least one of the mutant polypeptide of any one of claims 9 to 12, a polynucleotide encoding the same, and a vector comprising the polynucleotide; and a culture thereof.

18. A composition according to claim 17, wherein the microorganism has further enhanced activity of the AroP protein.

19. A method for producing carnosine, comprising a step of culturing a microorganism according to any one of claims 3 to 8 and 14 to 16 in a medium.

20. A method for producing carnosine, in claim 19, further comprising a step of recovering carnosine from at least one of the microorganism, a culture thereof, and a medium.

21. Use of a microorganism according to any one of claims 3 to 8 and 14 to 16 for producing carnosine.